Effect of Vonoprazan on Delayed Bleeding after Endoscopic Submucosal Dissection for Gastric Neoplasia among Antithrombotic Drug Users: A Single-Center, Single-Arm Prospective Observational Case Control Study by Yamamoto, Shumpei et al.
E ndoscopic submucosal dissection (ESD) is an accepted,  minimally invasive treatment for early 
gastric cancer [1 , 2].  Delayed bleeding is reported to be 
the most frequent adverse event of gastric ESD,  occur-
ring in 4-5% of patients [3 ,4].  Although risk factors such 
as tumor size,  location,  and procedure time have been 
associated with delayed bleeding [5-7],  use of anti-
thrombotic drugs may be a more important risk factor 
[6-9]; the reported bleeding rate in users of multiple 
antithrombotic drugs is 14-35% [10 , 11].  Proton pomp 
inhibitors (PPIs) are commonly used in attempts to heal 
the artifactual gastric ulcer caused by ESD and to prevent 
delayed bleeding after the procedure.  The efficacy of 
PPIs for post-ESD delayed bleeding has been reported 
[11 , 12].  It has been expected that vonoprazan,  a new,  
novel potassium-competitive acid blocker,  would be 
more effective than conventional PPIs in preventing 
delayed bleeding after gastric ESD because of its more 
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Antithrombotic therapy is a major risk factor for delayed bleeding after endoscopic submucosal dissection 
(ESD) for gastric neoplasia.  A potassium-competitive acid blocker,  vonoprazan,  is expected to prevent delayed 
bleeding better than conventional proton pomp inhibitors (PPIs),  but the evidence is controversial.  We sought 
to clarify the efficacy of vonoprazan for prevention of delayed bleeding after gastric ESD in patients under anti-
thrombotic therapy.  We prospectively registered 50 patients who underwent gastric ESD while receiving anti-
thrombotic therapy and vonoprazan in our institution between October 2017 and September 2018.  The inci-
dence of delayed bleeding was compared with that in a historical control group of 116 patients treated with 
conventional PPI.  We also evaluated risk factors associated with delayed bleeding.  Delayed bleeding was 
observed in 8 of 50 patients (16.0%),  which was not dissimilar from the incidence in the historical control 
group (12.1%) (p= 0.49).  In the univariate analysis,  age (> 70 years) (p= 0.034),  multiple antithrombotic drug 
use (p< 0.01),  procedure time (> 200 min) (p= 0.038) and tumor size (> 40 mm) (p< 0.01) were associated with 
delayed bleeding after gastric ESD,  but vonoprazan was not (p= 0.49).  Vonoprazan may not be more effective 
than conventional PPIs in preventing delayed bleeding after gastric ESD in patients receiving antithrombotic 
therapy.
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rapid,  potent,  and sustained acid inhibition,  but the 
results of the relevant studies have been conflicting 
[13 , 14].  Therefore,  we conducted a prospective obser-
vational case control study to evaluate the efficacy of 
vonoprazan for prevention of delayed bleeding in gas-
tric ESD among patients receiving antithrombotic ther-
apy.
Patients and Methods
Patients. Patients who were taking at least one 
antithrombotic drug and treated with gastric ESD at 
Kurashiki Central Hospital between October 2017 and 
September 2018 were prospectively enrolled in this study.  
Inclusion criteria were as follows: patients > 20 years 
old,  having lesions indicated for ESD based on endo-
scopic and pathological findings,  and taking anti-
thrombotic agents which could be managed according to 
the guidelines proposed by the Japan Gastroenterological 
Endoscopy Society in 2012 and 2017 [15 , 16].  Patients 
with perforation during ESD or patients for whom the 
management of antithrombotic drugs appeared to deviate 
from the protocols in the 2 guidelines were excluded.  
Although most antithrombotic agents were resumed on 
the next day after ESD,  it was the operator’s decision when 
to resume the drugs according to the risk of thrombosis 
and bleeding in each patient.  Written informed consent 
was obtained from all patients prior to treatment.  The 
study protocol was approved by the Research Ethics 
Committee of our hospital and was registered in the 
University Hospital Medical Network Clinical Trial 
Registry (UMIN000029300).  
Study protocol. Patients took vonoprazan 20 mg 
several hours before ESD and received an intravenous 
infusion of omeprazole 20 mg on the evening of the day 
of treatment.  All patients underwent a second-look 
endoscopy on the day after ESD,  and preventive hemo-
stasis was performed according to the endoscopists’ 
decision.  Oral vonoprazan of 20 mg/day was started 
after second-look endoscopy and continued for 4 weeks.  
Four weeks after ESD,  patients visited our outpatient 
clinic,  where they were informed of the histopathology 
of the resected lesions and were queried about post-ESD 
adverse events.
As a historical control group,  116 patients who were 
receiving antithrombotic therapy and underwent gastric 
ESD between January 2014 and December 2016 were 
analyzed.  The inclusion and exclusion criteria were the 
same as those for the vonoprazan group,  and all 
patients who met the criteria were enrolled.  All patients 
had been given an intravenous dose of 20 mg omepra-
zole twice on the day of and twice on the day after ESD.  
Oral administration of esomeprazole 20 mg/day was 
started on Day 3 after ESD and continued until 4 weeks 
after ESD.
Delayed bleeding was defined as hematemesis or 
melena requiring emergent upper endoscopy or a decrease 
of hemoglobin concentration of more than 2 g/dl from 
the pre-ESD value.  The incidence of delayed bleeding 
was compared between the vonoprazan group and his-
torical control group,  and risk factors associated with 
delayed bleeding were evaluated.  When multiple lesions 
were consecutively resected,  the total size of the lesions 
and total time for resection were used for the analysis.
Endoscopic procedures. Gastric ESD was per-
formed with these instruments: 1) a regular video 
endoscope (GIF-Q260J; Olympus,  Tokyo) and multi- 
bending endoscope (GIF-2TQ260M; Olympus); 2) an 
IT2 knife (KD-611L; Olympus),  an IT nano knife (KD- 
612L; Olympus) or a Dual Knife (KD-650L; Olympus);  
and 3) a VIO 300D electrosurgical unit (ERBE,  Tubingen,  
Germany).  
Statistical analysis. The JMP version 14.0 soft-
ware package (SAS Institute,  Cary,  NC,  USA) was used 
for all statistical analyses.  Continuous variables were 
expressed as the median and range and assessed by 
Student’s t-test or nonparametric tests.  Pearson’s chi-
squared test or Fisher’s exact test was performed to 
compare categorical variables.  Differences were consid-
ered significant at a p-value of less than 0.05.  
Results
Patient characteristics. Baseline characteristics 
of patients are listed in Table 1.  There were no signifi-
cant differences between patients in the vonoprazan 
group and those in the control group with respect to 
age,  rates of cardiovascular disease,  history of smoking,  
renal failure,  hemodialysis,  liver cirrhosis,  and diabe-
tes mellitus,  but significantly fewer patients in the con-
trol group were male and had hypertension.
Characteristics of the gastric lesions are listed in 
Table 2.  Tumors in the vonoprazan group were larger 
than those in the control group (p = 0.033),  but there 
were no significant differences between the 2 groups in 
terms of the location of the tumors in the stomach,  
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morphology and histopathology of the lesions,  rates of 
en bloc resection,  preventive hemostasis at second-look 
endoscopy,  rates of R0 resection,  or experience of the 
endoscopists.
Characteristics and management of antithrombotic 
agents. The patterns of use of antithrombotic agents 
are listed in Table 3.  Single antiplatelet drug use was 
marginally more common in the vonoprazan group 
than in the control group (p= 0.05).  Fewer patients were 
treated with heparin replacement in the vonoprazan 
group than in the control group,  but the number of 
patients who received heparin replacement was low,  
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Table 1　 Characteristics of patients
Vonoprazan group Historical control p value
Number of patients 50 116
Age,  median (range),  years 78 (54-87)  75 (59-87) 0.078
Sex/male (%) 33 (66.0%) 100 (86.2%) 0.0038
History of smoking (%) 23 (46%)  63 (54.3%) 0.33
Cardiovascular disease (%) 29 (58.0%)  70 (60.3%) 0.78
＊Renal failure (%) 23 (46%)  42 (36%) 0.24
Hemodialysis (%)  1 ( 2%)   4 ( 3.5%) 0.62
Liver cirrhosis (%)  0 ( 0%)   1 ( 0.8%) 0.39
Hypertension (%) 24 (48.0%)  81 (69.8%) 0.0074
Diabetes mellitus (%) 10 (20%)  40 (34.5%) 0.062
＊Renal failure: eGFR <60 mL/min
Table 2　 Characteristics of the lesions
Vonoprazan Historical control p value
Tumor located in the antrum,  (%)  13 (  7.8)  37 (22.3) 0.44
Morphology/elevated type: 0-Ⅰ or Ⅱa,  (%)  18 ( 36.0%)  56 (48.3%) 0.14
Tumor size (mm),  median (range)  45 ( 15-90)  37 (18-104) 0.033
Tumor with ulcer,  (%)   2 (  4.0%)   6 ( 5.2%) 0.74
Pathological findings/Adenoma or Differentiated type,  (%)  47 ( 95.9%) 115 (99.1%) 0.15
Tumor depth/Mucosal layer,  (%)  47 ( 95.9%) 104 (89.7%) 0.19
En bloc resection,  (%)  50 (100%) 113 (97.4%) 0.25
Procedure time,  median (range) 107 ( 30-326) 101 (27-383) 0.96
Preventive hemostasis at second-look endoscopy,  (%)  29 ( 58.0%)  77 (66.4%) 0.30
R0 resection,  (%)  46 ( 92.0%) 107 (92.2%) 0.96
Experience of endoscopist >6 years,  (%)  26 ( 52.0%)  51 (44.0%) 0.34






Single antiplatelet drug user 34 (68.0%) 60 (51.7%) 0.05
Single anticoagulant drug user  8 (16.0%) 28 (24.1%) 0.24
Multiple antithrombotic drugs user  8 (16.0%) 28 (24.1%) 0.24
Single aspirin user 18 (34.0%) 36 (31.0%) 0.71
Single thienopyridine user  5 ( 8.0%) 15 (12.9%) 0.35
Dual antiplatelet therapy  5 (10.0%) 22 (19.0%) 0.15
DOAC  9 (18.0%) 17 (14.7%) 0.59
Warfarin  3 ( 6.0%) 18 (15.5%) 0.09
Heparin replacement  2 ( 4.0%) 17 (14.7%) 0.048
Warfarin continue  1 ( 2%)  1 ( 0.86%) 0.50
DOAC,  direct oral anticoagulant.
and the difference was marginal (p = 0.048); the differ-
ence may have been due to changes made by the Japan 
Gastroenterological Endoscopy Society in 2017 to the 
guidelines for endoscopy in patients undergoing anti-
thrombotic treatment [15].  The management of anti-
thrombotic drugs is summarized in Table 4.  In the 
vonoprazan group,  direct oral anticoagulants (DOAC) 
were more frequently discontinued according to the 
2017 guidelines and restarted on the next morning than 
in the historical control group (p < 0.01).  Antiplatelet 
drugs were mostly discontinued following the 2012 
guidelines in both groups,  but were restarted signifi-
cantly earlier in the vonoprazan group than in the con-
trol group (p = 0.012).  Additionally,  any antithrombotic 
drugs were restarted significantly earlier in the vono-
prazan group (p < 0.01).
Outcomes. Delayed bleeding was observed in 8 
of 50 patients treated with vonoprazan (16.0%,  95% 
confidence interval 8.3-28.5%),  which was not signifi-
cantly different from the percentage of incidence in the 
historical group (12.1%,  7.3-19.2%) (p = 0.49) (Table 5).  
The incidence of delayed bleeding in patients with sin-
gle anticoagulant treatment tended to be higher in the 
vonoprazan group (25%,  2/8) than the control group 
(3.6%,  1/28) (p = 0.05),  but the number of patients 
treated was low.  Earlier resumption of any antithrom-
botic drugs was not significantly associated with a dif-
ference in delayed bleeding between the 2 groups.  All 
delayed bleeding was successfully managed with endo-
scopic hemostasis,  and none of the patients needed 
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＊following the 2017 guidelines  7/ 9 (77.8%)  1/ 17 ( 5.9%) 0.0004
Cessation of any antiplatelet drug
＊＊following the 2012 guidelines 38/42 (90.5%) 72/ 88 (81.8%) 0.29
Resumption of DOAC
continue or restart until the following day  8/ 9 (88.9%)  3/ 17 (17.6%) 0.0008
Resumption of any antiplatelet drug
continue or restart until the following day 33/42 (78.6%) 49/ 88 (55.7%) 0.012
Resumption of any antithrombotic drugs
continue or restart until the following day 44/50 (88%) 57/116 (49.1%) <0.0001
＊The Japanese Gastroenterological Endoscopy Society revised the guidelines in 2017 (see the 2017 appendix).
＊＊The Japanese Gastroenterological Endoscopy Society revised the guidelines in 2012.
Table 5　 Incidence of delayed bleeding
Vonoprazan group Historical control p value
Delayed bleeding 8/50




Single antiplatelet drug user 4/34 (11.8%) 4/60 ( 6.7%) 0.39
Single anticoagulant drug user 2/ 8 (25.0%) 1/28 ( 3.6%) 0.05
Multiple antithrombotic drugs user 2/ 8 (25.0%) 9/28 (32.1%) 0.70
Single aspirin user 2/18 (11.1%) 3/36 ( 8.3%) 0.75
Single thienopyridine user 0/ 5 ( 0%) 1/15 ( 6.7%) 0.44
Single another antiplatelet user 2/11 (18.2%) 0/ 9 ( 0%) 0.49
Dual antiplatelet therapy 2/ 5 (40.0%) 7/22 (31.2%) 0.73
DOAC 1/ 9 (11.1%) 1/17 ( 5.9%) 0.63
Heparin replacement 1/ 2 (50.0%) 3/17 (17.6%) 0.26
Resumption of any antithrombotic drugs 6/44 (13.6%) 7/57 (12.3%) 1.00continue or restart until the following day
blood transfusion.  No adverse events other than 
delayed bleeding,  including thromboembolic events,  
were recorded in the study population.  
Risk factors for delayed bleeding. In the univari-
ate analysis,  age (> 70 years) (odds ratio 0.35,  95% 
confidence interval 0.13-0.95,  p = 0.034),  multiple anti-
thrombotic drug use (odds ratio 4.76,  1.86-12.2,  
p < 0.01),  procedure time (> 200 min) (3.24,  1.02-10.3,  
p = 0.038) and tumor size (> 40 mm) (4.25,  1.49-12.1,  
p < 0.01) were associated with delayed bleeding after 
gastric ESD,  but vonoprazan use was not (1.38,  0.54-
3.55,  p = 0.49) (Table 6).
Discussion
In this prospective study,  the incidence of delayed 
bleeding after gastric ESD treated by vonoprazan was 
16% in patients under antithrombotic therapy,  which 
was not significantly different from that in patients 
treated with conventional PPIs (12.1%).  Two previously 
reported prospective studies on the prevention pf 
delayed bleeding after gastric ESD have yielded conflict-
ing results [13 , 14].  Hamada et al.  [13] reported that 
delayed bleeding occurred in 4.3% of vono-
prazan-treated patients and in 5.7% of patients treated 
with conventional PPIs,  an insignificant difference.  In 
contrast,  Kagawa et al.  [14] reported that vono-
prazan-treated patients had a significantly lower inci-
dence of delayed bleeding than did a historical group of 
patients treated with conventional PPIs (1.3%,  1/75 
patients vs.  10.0%,  15/150 patients); even in the sub-
group of patients receiving antithrombotic therapy,  the 
incidence of bleeding in patients treated with vono-
prazan (0%,  0/15) was significantly lower than that in 
patients treated with conventional PPIs (25%,  6/24) 
[14].  In their study,  however,  the incidence of delayed 
bleeding in the historical PPI group was higher than 
those in the earlier reports [3 , 4 , 11] and that in the 
present study.
In previous studies [6-9],  multiple antithrombotic 
drug use and tumor size were identified as independent 
risk factors associated with delayed bleeding after gastric 
ESD.  Vonoprazan was more effective than lansoprazole 
in preventing bleeding from low-dose aspirin-induced 
ulcers,  especially in patients receiving additional anti-
thrombotic drugs [17].  Thus,  we expected to observe a 
lower rate of delayed bleeding after gastric ESD in the 
vonoprazan group than the conventional PPI-treated 
group,  but this was not the case; the incidence of 
delayed bleeding was similar between the vonoprazan 
and conventional PPI groups,  even in patients receiving 
multiple antithrombotic drugs.  
There were several limitations of our study.  First,  we 
compared the incidence of bleeding of the vonoprazan 
group with that of a historical control group.  In 2017,  
the Japanese Gastroenterological Endoscopy Society 
revised the guidelines (2017 appendix) [15 , 16] for the 
management of antithrombotic agents during endo-
scopic procedures with bleeding risk,  taking the risk of 
thromboembolic events due to drug cessation into 
account rather than bleeding risk.  Thus,  the differences 
in the management of antithrombotic drugs between the 
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Table 6　 Risk factors associated with delayed bleeding
Univariate analysis 
Variable Odds ratio (95% CI) p value
Vonoprazan 1.38 (0.54-3.55) 0.49
Age >70 0.35 (0.13-0.95) 0.034
Sex: male 2.74 (0.61-12.4) 0.25
Multiple antithrombotic drugs user 4.76 (1.86-12.2) 0.0005
Procedure time >200 min 3.24 (1.02-10.3) 0.038
Tumor size >40 mm 4.25 (1.49-12.1) 0.0041
Cardiovascular disease 1.21 (0.48-3.08) 0.68
Heparin bridge 1.91 (0.57-6.40) 0.29
Renal failure 1.35 (0.55-3.33) 0.64
Hypertension 1.02 (0.40-2.59) 0.97
History of smoking 1.40 (0.57-3.49) 0.54
Resumption of any antithrombotics
1.12 (0.35-3.6) 0.84continue or restart until the following day
groups could have influenced the results.  In fact,  more 
patients in the vonoprazan group were treated with 
shorter interruption of DOAC or any antithrombotic 
agents,  but the early resumption of antithrombotic 
agents was not associated with ESD-related bleeding 
risk.  Second,  the number of subjects in this study may 
not have been large enough to reveal a difference in the 
effect of vonoprazan vs.  conventional PPIs on the 
delayed bleeding.  There had been no report on the risk 
of delayed bleeding after ESD in patients receiving anti-
thrombotics therapy with vonoprazan when we planned 
this prospective study.  Therefore,  the sample size deci-
sion was difficult,  and in the end we elected to conduct 
this research as a pilot study with a historical control.  
As a result,  the number of cases with delayed bleeding 
was insufficient to perform a multivariate logistic 
regression analysis.  However,  our pilot study is 
expected to lead to further large-scale prospective stud-
ies.  Third,  we should consider the selection bias of 
patients in the historical control group.  To reduce this 
bias,  we included all cases who satisfied the inclusion 
criteria during the study period.  Thus,  we could not 
adjust the background characteristics between the 2 
groups.  
In conclusion,  the incidence of delayed bleeding 
after gastric ESD in patients receiving antithrombotic 
therapy was not different between patients treated with 
vonorozan and those treated with conventional PPIs.  To 
further assess the putative effectiveness of vonoprazan 
in the prevention of bleeding after ESD of gastric lesions 
in patients receiving antithrombotic therapy,  large-
scale,  prospective studies should be conducted.
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